Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

Pillar's targeted assays help oncologists and researchers identify mutations that drive tumour growth. This knowledge is pivotal in making informed decisions about cancer treatment. By gaining an understanding of the genomic landscape of the tumour, clinicians can tailor treatment options such as targeted therapies and immunotherapies to suit each patient's needs.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/N8lzI3a
via